TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change from baseline in clinically significant abnormal values in laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensive Care Unit Need
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage change in Hepatic Venous Pressure Gradient (HVPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: valve intervention or follow-up visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EEG responses in the time domain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Posterior Trunk Symmetry Index (POTSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walter Reed Visual Assessment Scale (WRVAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence risk of P vivax
Endpoint domain: Adverse events/effects
Primary endpoint: visual clarity during ankle arthroscopic surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgeon's discomfort related to bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants That Completed Patient Quality of Life Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of treatment emergent adverse events (TEAE) and serious TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Changes over time in height Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lung cancer screening adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change of LV strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients achieving durable (non-relapsing) cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival margin distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival contour width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival volume in BL & MD aspects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Schirmer's 1 test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical impact and effectiveness of tumor surveillance strategies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mental Motor Chronometry (MMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving disease complete remission or partial remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of reported cases of PML
Endpoint domain: Adverse events/effects
Primary endpoint: Number of documented exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Change in EDSS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of new MRI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in nasal polyps score (NPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gingival bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Complete Remission (CR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Computer-Based Sustainable Attention Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individual Job Performance Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Patient Reported Quality of Recovery-15 (QOR15) score after major inpatient surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient Reported Quality of Recovery-15 (QOR15) score after minor inpatient surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient Reported Quality of Recovery-15 (QOR15) score after outpatient surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of definite intraoperative awareness with recall
Endpoint domain: Adverse events/effects
Primary endpoint: area under the curve of o~t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the curve of o~∞
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Anagen hair density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sit to reach test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Elimination of viruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum neurofilament light chain (NfL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum glial fibrillary acid protein (GFAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants with Treatment-related AEs (TRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Infant gut microbiome (RA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant gut microbiome (alpha diversity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant gut microbiome (beta diversity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of child's symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Active Shoulder Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Force Tracking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Field Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal RBC folate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maternal serum folate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neural synchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in lactulose:mannitol ratio in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants who Experience One or More Bleeding Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants who Discontinue Study Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration-Time Curve from 0 to Infinity (AUC0-inf) of MK-2060
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average joint pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: [18F]NOS uptake (distribution volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence to Flash 1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Selective Control Assessment of the Lower Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boyd and Graham SMC Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thigh muscle strength score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: rate of immediate pre operative anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in the Sjogren's Tool for Assessing Response (STAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mesorectal Fat Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western-Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Knee Joint Proprioception Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric difference of the deficient interdental papilla
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric difference of the interdental bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Submental fat thickness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Complete Response Rate (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average level of moderate to vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day Point Prevalence Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in interincisal distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of JP-1366
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of JP-1366
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody titres against the 4 vaccine antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of hearing abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (ORR) based on RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportional change in NT-proBNP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and frequency of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and characteristics (severity, outcome, etc.) of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of clinically significant abnormal echocardiography results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Antiviral activity - Percentage of participants who maintain plasma HIV RNA <1000 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative venous thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Fitzpatrick- Goldman Classification of Wrinkling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Degree of Elastosis Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in gut microbiota bifidobacterial levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of participants who completed the 12-week intervention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Average number of provided foods consumed during the day over the course of the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who completed the Mixed-meal tolerance test at the 12-week visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of photon counting/spectral CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Treatment-related Adverse Events (AE) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: PIVC-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life (QoL) score rating
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants that had trouble adhering to the study drug schedule
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants satisfied with their opportunities to interact with study staff
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change over time in Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change over time in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in in-ear movements (IEMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of dyspnea
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quantification of movement disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gut microbiota diversity and richness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gut microbiota metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in FEV1 % Predicted at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change from baseline body weight at 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline fasting glucose in mg/dl at 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change from baseline blood pressure in mmHg at 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mechanical device closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with Advanced Care Planning
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of subjects with complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival without moderate to severe neurodevelopmental disability
Endpoint domain: Mortality/survival
Primary endpoint: Leeds assessment of neuropathic symptoms and sign (LANSS) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain-free hand grip test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time required for sensory recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Orthognathic Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Objective Response Rate (ORR) Based on iRECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in pain score for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain score for numbness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain score for weakness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative frequency of successful acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline pain intensity and interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid profile control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of supracrestal width (CEJ-AC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in PART-1: SAD
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Change From Baseline in Vital Signs in PART-1: SAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Laboratory Abnormalities in PART-1: SAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Unified Myoclonus Rating Scale (UMRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assess Health-Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ventilator day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Expression Adjusted by Muscle Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Expression in Biopsied Muscle as Measured by Immunofluorescence (IF) Fiber Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Concentration of Vector Genome Copies Using Polymerase Chain Reaction in Muscle Tissue Biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: App usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of device deficiencies
Endpoint domain: Adverse events/effects
Primary endpoint: C-reactive protein to Albumin ratio (CAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Calf Muscle Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of BAT8006
Endpoint domain: Adverse events/effects
Primary endpoint: Number of AEs, TEAEs, related TEAEs, Grade 3/4 TEAEs, and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in electrocardiogram (ECG) parameter - heart rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in echocardiogram (ECHO) parameter - ejection fraction (EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of adverse events/reactions within 1 month
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of serious adverse events/reactions within 6 months
Endpoint domain: Adverse events/effects
Primary endpoint: Abnormal occurrence of laboratory indicators 3 days after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area Under the Curve (AUC) of Pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough Concentration (Ctrough) of Pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in adherence to a healthy lifestyle score at 24 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in adherence to a healthy lifestyle score at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximal Aerobic Capacity (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 7-day pneumonia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Insulin Resistance Index (HOMA-IR) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: severity of DKA at presentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term prognosis of patients with DKA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants diagnosed with advanced aortic stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pocket hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Root caries incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric pain scale rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma-related Quality of life questionnaire (AQLQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Adverse Events during the study
Endpoint domain: Adverse events/effects
Primary endpoint: Time to resolution of clinical symptoms related to RSV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of subjects achieving symptom remission & disease remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leaflet splitting success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of undetectable minimal residual disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Discontinuing from Study Therapy due to AE
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: No worsening of NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes